Sam Chun Dang Pharm. Co. Ltd (000250) - Net Assets

Latest as of September 2025: ₩354.99 Billion KRW ≈ $240.57 Million USD

Based on the latest financial reports, Sam Chun Dang Pharm. Co. Ltd (000250) has net assets worth ₩354.99 Billion KRW (≈ $240.57 Million USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩529.96 Billion ≈ $359.14 Million USD) and total liabilities (₩174.97 Billion ≈ $118.57 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check 000250 financial resilience to evaluate the company's liquid asset resilience ratio.

Key Net Assets Metrics

Metric	Value
Current Net Assets	₩354.99 Billion
% of Total Assets	66.98%
Annual Growth Rate	9.8%
5-Year Change	42.59%
10-Year Change	132.78%
Growth Volatility	22.94

Sam Chun Dang Pharm. Co. Ltd - Net Assets Trend (2012–2024)

This chart illustrates how Sam Chun Dang Pharm. Co. Ltd's net assets have evolved over time, based on quarterly financial data. Also explore Sam Chun Dang Pharm. Co. Ltd assets under control for the complete picture of this company's asset base.

Annual Net Assets for Sam Chun Dang Pharm. Co. Ltd (2012–2024)

The table below shows the annual net assets of Sam Chun Dang Pharm. Co. Ltd from 2012 to 2024. For live valuation and market cap data, see Sam Chun Dang Pharm. Co. Ltd stock valuation.

Year	Net Assets	Change
2024-12-31	₩266.11 Billion ≈ $180.34 Million	-10.84%
2023-12-31	₩298.46 Billion ≈ $202.26 Million	+71.78%
2022-12-31	₩173.74 Billion ≈ $117.74 Million	-0.20%
2021-12-31	₩174.09 Billion ≈ $117.98 Million	-6.71%
2020-12-31	₩186.63 Billion ≈ $126.47 Million	+18.21%
2019-12-31	₩157.87 Billion ≈ $106.99 Million	+6.30%
2018-12-31	₩148.52 Billion ≈ $100.65 Million	+5.08%
2017-12-31	₩141.34 Billion ≈ $95.78 Million	+12.92%
2016-12-31	₩125.17 Billion ≈ $84.82 Million	+9.49%
2015-12-31	₩114.32 Billion ≈ $77.47 Million	-18.16%
2014-12-31	₩139.68 Billion ≈ $94.66 Million	+17.15%
2013-12-31	₩119.23 Billion ≈ $80.80 Million	+37.63%
2012-12-31	₩86.63 Billion ≈ $58.71 Million	--

Equity Component Analysis

This analysis shows how different components contribute to Sam Chun Dang Pharm. Co. Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

Retained earnings have grown by 66.3% over the analyzed period, indicating profitable operations and earnings retention.

Current Equity Component Breakdown (December 2024)

Component	Amount	Percentage
Retained Earnings	₩95.45 Billion	35.87%
Common Stock	₩11.73 Billion	4.41%
Other Components	₩158.92 Billion	59.72%
Total Equity	₩266.11 Billion	100.00%

Sam Chun Dang Pharm. Co. Ltd Competitors by Market Cap

The table below lists competitors of Sam Chun Dang Pharm. Co. Ltd ranked by their market capitalization.

Company	Market Cap
Hyundai Mipo Dockyard KO:010620	$6.03 Billion
Vipshop Holdings Limited NYSE:VIPS	$6.03 Billion
Ringkjoebing Landbobank A/S CO:RILBA	$6.03 Billion
Zhejiang Hailiang Co Ltd SHE:002203	$6.03 Billion
BNP Paribas Bank Polska S.A. WAR:BNP	$6.02 Billion
Innolux Corp TW:3481	$6.02 Billion
Gruma S.A.B. de C.V. MX:GRUMAB	$6.02 Billion
Shan Dong Sun Paper Industry Joint Stock Co Ltd SHE:002078	$6.02 Billion

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Sam Chun Dang Pharm. Co. Ltd's equity between the two most recent reporting periods.

Equity Growth Insights

From 2023 to 2024, total equity changed from 220,498,640,040 to 266,105,335,240, a change of 45,606,695,200 (20.7%).
Net loss of 10,916,104,970 reduced equity.
Dividend payments of 890,150,900 reduced retained earnings.
Share repurchases of 71,215,115,460 reduced equity.
New share issuances of 71,215,115,450 increased equity.
Other factors increased equity by 57,412,951,080.

Equity Change Factors (2023 to 2024)

Factor	Impact	Contribution
Net Income	₩-10.92 Billion	-4.1%
Dividends Paid	₩890.15 Million	-0.33%
Share Repurchases	₩71.22 Billion	-26.76%
Share Issuances	₩71.22 Billion	+26.76%
Other Changes	₩57.41 Billion	+21.58%
Total Change	₩-	20.68%

Book Value vs Market Value Analysis

This analysis compares Sam Chun Dang Pharm. Co. Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

Current price-to-book ratio: 36.31x
The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
The price-to-book ratio has decreased from 70.71x to 36.31x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date	Book Value per Share	Market Price	P/B Ratio
2016-12-31	₩5876.20	₩415500.00	x
2017-12-31	₩6602.83	₩415500.00	x
2018-12-31	₩6938.23	₩415500.00	x
2019-12-31	₩7375.20	₩415500.00	x
2020-12-31	₩8456.84	₩415500.00	x
2021-12-31	₩7889.00	₩415500.00	x
2022-12-31	₩7872.97	₩415500.00	x
2023-12-31	₩9718.51	₩415500.00	x
2024-12-31	₩11441.71	₩415500.00	x

Capital Efficiency Dashboard

This dashboard shows how efficiently Sam Chun Dang Pharm. Co. Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

Current Return on Equity (ROE): -4.10%
The company may be facing challenges in efficiently utilizing shareholder equity.
DuPont Analysis Breakdown:
• Net Profit Margin: -5.18%
• Asset Turnover: 0.41x
• Equity Multiplier: 1.95x
Recent ROE (-4.10%) is below the historical average (3.48%), suggesting potential challenges in capital efficiency.

Historical Capital Efficiency Metrics

Year	Return on Equity	Net Profit Margin	Asset Turnover	Equity Multiplier	Economic Value Added
2012	1.63%	1.75%	0.63x	1.49x	₩-6.87 Billion
2013	9.37%	8.34%	0.67x	1.67x	₩-588.58 Million
2014	11.24%	9.96%	0.69x	1.64x	₩1.30 Billion
2015	10.17%	8.81%	0.72x	1.61x	₩196.52 Million
2016	6.96%	5.91%	0.72x	1.64x	₩-3.80 Billion
2017	8.85%	7.79%	0.70x	1.63x	₩-1.62 Billion
2018	5.89%	5.47%	0.61x	1.76x	₩-6.10 Billion
2019	6.62%	5.60%	0.64x	1.84x	₩-5.34 Billion
2020	-0.52%	-0.58%	0.53x	1.70x	₩-19.63 Billion
2021	-9.51%	-9.90%	0.48x	1.99x	₩-33.96 Billion
2022	3.36%	3.29%	0.48x	2.15x	₩-11.54 Billion
2023	-4.71%	-5.39%	0.47x	1.85x	₩-32.43 Billion
2024	-4.10%	-5.18%	0.41x	1.95x	₩-37.53 Billion

Industry Comparison

This section compares Sam Chun Dang Pharm. Co. Ltd's net assets metrics with peer companies in the Pharmaceuticals industry.

Industry Context

Industry: Pharmaceuticals
Average net assets among peers: $75,197,174,012
Average return on equity (ROE) among peers: -0.26%

Peer Company Comparison

Company	Net Assets	Return on Equity	Debt-to-Equity	Market Cap
Sam Chun Dang Pharm. Co. Ltd (000250)	₩354.99 Billion	1.63%	0.49x	$6.03 Billion
DongKoo Bio&Pharma Co. Ltd (006620)	$102.11 Billion	6.48%	0.69x	$33.52 Million
NatureCell Co.Ltd (007390)	$-16.60 Million	0.00%	0.00x	$688.81 Million
Sam-A Pharm. Co. Ltd (009300)	$79.92 Billion	4.39%	0.39x	$68.66 Million
Kyung Dong Pharmaceutical Co. Ltd (011040)	$150.62 Billion	13.47%	0.23x	$89.89 Million
WooGene B&G Co. Ltd (018620)	$22.14 Billion	0.79%	1.63x	$13.13 Million
Oscotec Inc (039200)	$94.72 Billion	-25.63%	0.40x	$990.30 Million
EstechPharma Co. Ltd (041910)	$115.63 Billion	3.31%	0.05x	$59.21 Million
Komipharm International Co. Ltd (041960)	$76.13 Billion	-8.60%	0.75x	$380.81 Million
Eagle Veterinary Technology Co.Ltd (044960)	$35.53 Billion	3.47%	0.29x	$34.35 Million

About Sam Chun Dang Pharm. Co. Ltd

KQ:000250 Korea Pharmaceuticals

Market Cap

$6.03 Billion

₩8.89 Trillion KRW

Market Cap Rank

#3165 Global

#81 in Korea

Share Price

₩415500.00

Change (1 day)

-6.21%

52-Week Range

₩130900.00 - ₩1000000.00

All Time High

₩1000000.00